Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tyra Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Tyra Biosciences, Inc.

TYRA

Tyra Biosciences, Inc.

About Tyra Biosciences, Inc.

Tyra Biosciences is a clinical-stage biotech focused on developing precision medicines targeting FGFR biology for oncology and genetically defined conditions. Its in-house SNÅP platform enables rapid, selective drug design. Core programs include FGFR3 inhibitors for bladder cancer and skeletal disorders, FGFR2 inhibitors for cholangiocarcinoma, and FGFR4/3 inhibitors for hepatocellular carcinoma, aiming to address unmet medical needs with innovative, targeted therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tyra Biosciences, Inc.

1
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $39.3 Million Net Loss and $412 Million in Total Assets for Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $119.9 Million Net Loss and Advances Pipeline in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $29.9 Million Net Loss in Q3 2025, Increased Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $28.1 Million Net Loss in Q2 2025, Increased Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $28.1 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tyra Biosciences, Inc. Tyra Biosciences Reports $86.48 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tyra Biosciences, Inc. Tyra Biosciences Reports Financial Developments, Increased Cash Reserves, and Ongoing Clinical Studies

Via official filing (AI summary) | over 1 year ago | 0 comments